Inaugural Miami Cancer Institute Precision Oncology Symposium - Evaluation - Day 2 - February 4, 2023

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence

	5	4	3	2	1
Properly diagnose and manage solid tumor malignancies.	Properly diagnose and manage solid tumor malignancies. - 5	Properly diagnose and manage solid tumor malignancies. - 4	Properly diagnose and manage solid tumor malignancies. - 3	Properly diagnose and manage solid tumor malignancies. - 2	Properly diagnose and manage solid tumor malignancies. - 1
Provide an update of new molecular and targeted treatments being developed for solid tumors.	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 5	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 4	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 3	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 2	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 1

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Precision Oncology Opportunities in Head and Neck Cancer - Everett Vokes, M.D.	Precision Oncology Opportunities in Head and Neck Cancer - Everett Vokes, M.D. - 5	Precision Oncology Opportunities in Head and Neck Cancer - Everett Vokes, M.D. - 4	Precision Oncology Opportunities in Head and Neck Cancer - Everett Vokes, M.D. - 3	Precision Oncology Opportunities in Head and Neck Cancer - Everett Vokes, M.D. - 2	Precision Oncology Opportunities in Head and Neck Cancer - Everett Vokes, M.D. - 1
Precision Oncology in Metastatic Prostate Cancer: Current and Emerging Paradigms - Neeraj Agarwal, M.D.	Precision Oncology in Metastatic Prostate Cancer: Current and Emerging Paradigms - Neeraj Agarwal, M.D. - 5	Precision Oncology in Metastatic Prostate Cancer: Current and Emerging Paradigms - Neeraj Agarwal, M.D. - 4	Precision Oncology in Metastatic Prostate Cancer: Current and Emerging Paradigms - Neeraj Agarwal, M.D. - 3	Precision Oncology in Metastatic Prostate Cancer: Current and Emerging Paradigms - Neeraj Agarwal, M.D. - 2	Precision Oncology in Metastatic Prostate Cancer: Current and Emerging Paradigms - Neeraj Agarwal, M.D. - 1
Applying Precision Medicine to Rare Subtypes of Renal Cell Carcinoma - Pal Sumanta, M.D.	Applying Precision Medicine to Rare Subtypes of Renal Cell Carcinoma - Pal Sumanta, M.D. - 5	Applying Precision Medicine to Rare Subtypes of Renal Cell Carcinoma - Pal Sumanta, M.D. - 4	Applying Precision Medicine to Rare Subtypes of Renal Cell Carcinoma - Pal Sumanta, M.D. - 3	Applying Precision Medicine to Rare Subtypes of Renal Cell Carcinoma - Pal Sumanta, M.D. - 2	Applying Precision Medicine to Rare Subtypes of Renal Cell Carcinoma - Pal Sumanta, M.D. - 1
ASCO’s Journey of Precision Medicine: The TAPUR Experience - Julie R. Gralow, M.D.	ASCO’s Journey of Precision Medicine: The TAPUR Experience - Julie R. Gralow, M.D. - 5	ASCO’s Journey of Precision Medicine: The TAPUR Experience - Julie R. Gralow, M.D. - 4	ASCO’s Journey of Precision Medicine: The TAPUR Experience - Julie R. Gralow, M.D. - 3	ASCO’s Journey of Precision Medicine: The TAPUR Experience - Julie R. Gralow, M.D. - 2	ASCO’s Journey of Precision Medicine: The TAPUR Experience - Julie R. Gralow, M.D. - 1
Precision Oncology Approaches in Gliomas - Patrick Wen, M.D.	Precision Oncology Approaches in Gliomas - Patrick Wen, M.D. - 5	Precision Oncology Approaches in Gliomas - Patrick Wen, M.D. - 4	Precision Oncology Approaches in Gliomas - Patrick Wen, M.D. - 3	Precision Oncology Approaches in Gliomas - Patrick Wen, M.D. - 2	Precision Oncology Approaches in Gliomas - Patrick Wen, M.D. - 1
Updates and Future Directions in the Management of Metastatic TNBC - Tiffany Traina, M.D.	Updates and Future Directions in the Management of Metastatic TNBC - Tiffany Traina, M.D. - 5	Updates and Future Directions in the Management of Metastatic TNBC - Tiffany Traina, M.D. - 4	Updates and Future Directions in the Management of Metastatic TNBC - Tiffany Traina, M.D. - 3	Updates and Future Directions in the Management of Metastatic TNBC - Tiffany Traina, M.D. - 2	Updates and Future Directions in the Management of Metastatic TNBC - Tiffany Traina, M.D. - 1
Precision Oncology Approaches in Melanoma - Pauline Funchain, M.D.	Precision Oncology Approaches in Melanoma - Pauline Funchain, M.D. - 5	Precision Oncology Approaches in Melanoma - Pauline Funchain, M.D. - 4	Precision Oncology Approaches in Melanoma - Pauline Funchain, M.D. - 3	Precision Oncology Approaches in Melanoma - Pauline Funchain, M.D. - 2	Precision Oncology Approaches in Melanoma - Pauline Funchain, M.D. - 1
Updates in the Management of Advanced/Metastatic Urothelial Carcinoma - Petros Grivas, M.D.	Updates in the Management of Advanced/Metastatic Urothelial Carcinoma - Petros Grivas, M.D. - 5	Updates in the Management of Advanced/Metastatic Urothelial Carcinoma - Petros Grivas, M.D. - 4	Updates in the Management of Advanced/Metastatic Urothelial Carcinoma - Petros Grivas, M.D. - 3	Updates in the Management of Advanced/Metastatic Urothelial Carcinoma - Petros Grivas, M.D. - 2	Updates in the Management of Advanced/Metastatic Urothelial Carcinoma - Petros Grivas, M.D. - 1

Was this course fair, balanced and without commercial bias? *

Yes

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will discuss the rationale for new targeted diagnostics and therapeutic strategies for lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcoma and brain tumors.

I will review the role and timing of diagnostic tests, molecular profiling and potential combinations of targeted therapy treatment options.

I will implement the use of plasma-based liquid biopsy approaches for molecular testing.

I will implement monitoring treatment responses for HPV ctDNA.

Not applicable to my practice.

I do not agree with the recommendations presented.

I am retired.

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name *

Attestation *

Choose 1 option

I attest that I have participated in this live symposium in its entirety.

I attest that I have participated in _____ hours of instruction during this live symposium.

hours attestation *

Hours attended

Leave this field blank

You are here

Inaugural Miami Cancer Institute Precision Oncology Symposium - Evaluation - Day 2 - February 4, 2023